全文获取类型
收费全文 | 6129篇 |
免费 | 286篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 169篇 |
妇产科学 | 110篇 |
基础医学 | 916篇 |
口腔科学 | 503篇 |
临床医学 | 538篇 |
内科学 | 1254篇 |
皮肤病学 | 138篇 |
神经病学 | 486篇 |
特种医学 | 97篇 |
外科学 | 650篇 |
综合类 | 27篇 |
一般理论 | 1篇 |
预防医学 | 613篇 |
眼科学 | 40篇 |
药学 | 399篇 |
中国医学 | 26篇 |
肿瘤学 | 406篇 |
出版年
2023年 | 57篇 |
2022年 | 90篇 |
2021年 | 155篇 |
2020年 | 105篇 |
2019年 | 142篇 |
2018年 | 183篇 |
2017年 | 108篇 |
2016年 | 137篇 |
2015年 | 155篇 |
2014年 | 223篇 |
2013年 | 250篇 |
2012年 | 460篇 |
2011年 | 551篇 |
2010年 | 287篇 |
2009年 | 231篇 |
2008年 | 397篇 |
2007年 | 410篇 |
2006年 | 382篇 |
2005年 | 364篇 |
2004年 | 325篇 |
2003年 | 282篇 |
2002年 | 250篇 |
2001年 | 65篇 |
2000年 | 78篇 |
1999年 | 83篇 |
1998年 | 60篇 |
1997年 | 43篇 |
1996年 | 41篇 |
1995年 | 39篇 |
1994年 | 40篇 |
1993年 | 34篇 |
1992年 | 34篇 |
1991年 | 33篇 |
1990年 | 30篇 |
1989年 | 30篇 |
1988年 | 16篇 |
1987年 | 26篇 |
1986年 | 26篇 |
1985年 | 21篇 |
1984年 | 19篇 |
1983年 | 22篇 |
1982年 | 16篇 |
1981年 | 15篇 |
1979年 | 9篇 |
1977年 | 9篇 |
1976年 | 8篇 |
1974年 | 11篇 |
1973年 | 8篇 |
1972年 | 16篇 |
1967年 | 8篇 |
排序方式: 共有6441条查询结果,搜索用时 15 毫秒
91.
92.
Cristian Patrick Zeni Silzá Tramontina Thamis Aline Zeni Roberta Coelho Gabriel Pheula Julio Bernardi Ursula Maldaner Talita Lopes Silva Angélica Salatino-Oliveira Mara Hutz Luis Augusto Rohde 《Revista brasileira de psiquiatria (S?o Paulo, Brazil : 1999)》2013,35(1):44-50
ObjectivesTo assess the role of the Val66Met polymorphism at the brain-derived neurotrophic factor (BDNF) gene on the performance of children and adolescents with bipolar disorder [juvenile bipolar disorder (JBD)] on the Wisconsin Card Sorting Test (WCST).MethodsChildren and adolescents were assessed by the K-SADS-PL and a clinical evaluation for BD and comorbid conditions. Manic and depressive symptoms were assessed with the Young Mania Rating Scale and the Children Depression Rating Scale – Reviewed. The Val66Met polymorphism at the BDNF was genotyped from a blood sample. Patients’ IQ and executive functions were assessed by a standard cognitive flexibility test (WCST).ResultsFifty-three subjects were included in the study. No significant difference was observed between the Val/Val and Val/Met+Met/Met groups on any WCST scores in the MANCOVA (F48,5 = .76; p = .59; Perseverative Errors, p = .66; Nonperseverative Errors, p = .58; Categories Completed, p = .34; Attempts to Reach First Category, p=.64; and Percentage of Conceptual Level Responses, p = .99).ConclusionsOur findings from this sample of children and adolescents with BD do not replicate results from studies of adults and suggest the existence of differences in the neurobiology of this disorder across the life cycle. Investigations of larger samples are necessary to confirm these data. 相似文献
93.
Larissa Fonseca da Cunha Sousa Fernanda Matos Coelho David Henrique Rodrigues Alline Cristina Campos Lucíola da Silva Barcelos Mauro Martins Teixeira Milene Alvarenga Rachid Antonio Lúcio Teixeira 《Clinics (S?o Paulo, Brazil)》2013,68(3):391-394
OBJECTIVE:
Ischemic stroke may result from transient or permanent reductions of regional cerebral blood flow. Polymorphonuclear neutrophils have been described as the earliest inflammatory cells to arrive in ischemic tissue. CXCR1/2 receptors are involved in the recruitment of these cells. However, the contribution of these chemokine receptors during transient brain ischemia in mice remains poorly understood. In this work, we investigated the effects of reparixin, an allosteric antagonist of CXCR1/2 receptors, in a model of middle cerebral artery occlusion and reperfusion in mice.METHODS:
C57BL/6J male mice treated with reparixin or vehicle were subjected to a middle cerebral artery occlusion procedure 1 h after the treatment. Ninety minutes after ischemia induction, the monofilament that prevented blood flow was removed. Twenty-four hours after the reperfusion procedure, behavioral changes, including motor signs, were analyzed with the SmithKline/Harwell/Imperial College/Royal Hospital/Phenotype Assessment (SHIRPA) battery. The animals were sacrificed, and brain tissue was removed for histological and biochemical analyses. Histological sections were stained with hematoxylin and eosin, neutrophil infiltration was estimated by myeloperoxidase activity and the inflammatory cytokine IL-1β was measured by ELISA.RESULTS:
Pre-treatment with reparixin reduced the motor deficits observed in this model of ischemia and reperfusion. Myeloperoxidase activity and IL-1β were reduced in the reparixin-treated group. Histological analysis revealed that ischemic injury was also attenuated by reparixin pre-treatment.CONCLUSIONS:
Our results suggest that the blockade of the CXCR1/2 receptors by reparixin promotes neuroprotective effects by reducing the levels of polymorphonuclear infiltration in the brain and the tissue damage associated with middle cerebral artery occlusion and reperfusion. 相似文献94.
Marlene Coelho da Costa Gabriela Unchalo Eckert Bárbara Gastal Borges Fortes Jo?o Borges Fortes Filho Rita C. Silveira Renato S Procianoy 《Clinics (S?o Paulo, Brazil)》2013,68(2):199-203
OBJECTIVE:
Ophthalmologic examination for retinopathy of prematurity is a painful procedure. Pharmacological and non-pharmacological interventions have been proposed to reduce pain during eye examinations. This study aims to evaluate the analgesic effect of 25% glucose using a validated pain scale during the first eye examination for retinopathy of prematurity in preterm infants with birth weight ≤1,500 g and/or gestational age ≤32 weeks.METHODS:
A masked, randomized clinical trial for one dose of 1 ml of oral 25% glucose solution 2 minutes before the first ophthalmologic examination for retinopathy of prematurity was conducted between March 2008 and April 2010. The results were compared to those of a control group that did not receive oral glucose solution. Pain was evaluated using a Neonatal Infant Pain Scale immediately before and immediately after the ophthalmologic examination in both groups. Clinicaltrials.gov: NCT00648687RESULTS:
One hundred and twenty-four patients who were examined for the first time for retinopathy of prematurity were included. Seventy were included in the intervention group and 54 in the control group. The number of patients with pain immediately before the procedure was similar in both groups. The number of patients with pain after ophthalmologic examination was 15.7% in the intervention group and 68.5% in the control group (p<0.001).CONCLUSIONS:
One ml of oral 25% glucose solution given 2 minutes before an ophthalmologic examination for retinopathy of prematurity was an effective measure for pain relief. 相似文献95.
Diego Coelho Lorenzoni Ana Carolina Cuzzuol Fracalossi Viviane Carlin Daniel Araki Ribeiro Eduardo Franzotti Sant'Anna 《The Angle orthodontist》2013,83(1):104
Objectives:To evaluate and compare mutagenicity (micronucleus) and cytotoxicity (karyorrhexis, pyknosis, and karyolysis) in exfoliated buccal mucosa cells of children following cone beam computed tomography (CBCT) or conventional radiograph exposure necessary for orthodontic planning.Materials and Methods:A total of 49 healthy children were submitted to CBCT or a conventional orthodontic radiographic protocol; they were divided into two groups based on exam: CBCT (n = 24) and Radiographic Set (n = 25) groups. The micronucleus test in the exfoliated buccal mucosa cells was applied.Results:There was not a statistically significant difference (P > .05) found between the number of micronucleated buccal mucosa cells (MNC) before and after exposure to radiation in either group, showing that neither group experienced a mutagenic effect. However, radiation did cause other nuclear alterations closely related to cytotoxicity, including karyorrhexis, pyknosis, and karyolysis, in both groups (P < .05). The CBCT group presented a greater increase in cell death than was noted in the Radiographic Set group (P < .044).Conclusion:According to the micronucleus test, mutagenicity was not induced by the CBCT or the conventional radiographs, but cytotoxicity was verified after these exams, especially after CBCT. That might have happened once the CBCT group received a greater radiation dose than the Radiographic Set group as a result of the protocols used in orthodontic planning for this study. 相似文献
96.
The prevention of mother-to-child HIV transmission (PMTCT) is a complex challenge in heavily affected and resource-limited settings such as South Africa. Management of PMTCT requires a cascade of interventions that need to be addressed to effectively decrease the risk of HIV transmission to infants. This PMTCT cascade includes incremental components that can be shaped and influenced by the patient-provider relationship. The relationship that a pregnant woman has with her care providers may possibly affect decisions that she makes concerning her antenatal care and may, in turn, influence the quality of the care provided. A patient-provider relationship scale (PPRS) was developed in Pretoria, South Africa with two aims: first, to quantify the patient-provider relationship in an antenatal population in a resource-limited setting and provide preliminary evidence of its reliability and validity; and second, to determine whether the patient-provider relationship has an effect on PMTCT. The instrument was administrated in a cross-sectional pilot study to a group of women at discharge after delivery (n=192) at two major hospitals in South West Tshwane. Statistical analysis of the instrument showed high reliability (α=0.91) and preliminary evidence of its validity including significant associations with participants' attitudes regarding the functioning of the clinics and a single statement (the clinic staff "know me as a person," R=0.47, p<0.001) that has been shown previously to have a significant association with adherence to antiretroviral treatment. For HIV-positive participants, the PPRS was significantly associated with statements related to important components of the PMTCT cascade. In addition, those with substantially inadequate antenatal care (≤2 visits) and those who did not initiate highly active antiretroviral therapy, although eligible, had significantly poorer PPRS scores. The PPRS is a potentially useful, context-appropriate instrument that could have an important role in future research focused on improving PMTCT and decreasing the risk of HIV infection in children. 相似文献
97.
98.
A Besarab SN Zeig ER Martin PE Pergola FC Whittier RI Zabaneh B Schiller M Mayo CA Francisco KR Polu AM Duliege 《BMC nephrology》2012,13(1):95
ABSTRACT: BACKGROUND: Peginesatide is a peptide-based erythropoiesis-stimulating agent that was designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. The primary objective of this phase 2 dose-finding study was to determine the once-monthly peginesatide dosing strategy that would maintain hemoglobin within [PLUS-MINUS SIGN]1.0 g/dL of baseline values after conversion from epoetin alfa; the safety of peginesatide was evaluated concurrently. METHODS: Chronic hemodialysis patients on stable regimens of epoetin alfa were sequentially assigned to cohorts that differed on (1) how the peginesatide starting dose was determined (using a single epoetin alfa--to-peginesatide dose conversion ratio or a tiered, weight-based or absolute-dose conversion table) and on (2) whether or not a 1-week erythropoiesis-stimulating agent-free interval was used. Peginesatide doses were titrated to maintain hemoglobin levels within [PLUS-MINUS SIGN]1.0 g/dL from baseline. RESULTS: A total of 164 patients were enrolled and received intravenous peginesatide every 4 weeks for up to 6 doses; the duration of the study including follow-up was [LESS-THAN OR EQUAL TO]29 weeks. Overall, the proportion of patients with hemoglobin levels within [PLUS-MINUS SIGN]1.0 g/dL of baseline increased over the course of the study from 39% (Weeks 2--13) to 54% (Weeks 18--25). Cohorts that used tiered dose conversion tables trended towards having more stable peginesatide doses than did those cohorts that used a single dose conversion ratio. Moreover, cohorts that used an erythropoiesis-stimulating agent-free interval did not have the substantial initial increase in hemoglobin levels that was seen in those cohorts that did not use such an interval. In this study, the safety profile of peginesatide was consistent with those of marketed erythropoiesis-stimulating agents. CONCLUSIONS: The results of this study were used to guide the dosing regimens used subsequently in phase 3 studies. Once-monthly peginesatide is feasible in hemodialysis patients.Trial registrationClinicalTrials.gov registration: NCT00228449. 相似文献
99.
100.
J. S. Passos M. I. P. Vianna I. S. Gomes-Filho S. S. Cruz M. L. Barreto L. Adan C. K. Rösing E. M. M. Cerqueira S. C. Trindade J. M. F. Coelho 《Osteoporosis international》2013,24(4):1275-1283